Effectiveness and Safety of Psoriasis Treatment Validated by Real-World Data Study

A new real-world data (RWD) of guselkumab, Janssen’s therapeutic for plaque psoriasis, confirmed the safety and efficacy that was demonstrated in randomized controlled trials (RCTs). Data from 79 people with moderate to severe plaque psoriasis. The majority of participants had a 90% or higher reduction in the plaque area and intensity index (PASI).

According to Rob Volansky, “At week 28, 92% of patients reached PASI 50 or higher, 82% reached PASI 75 or higher and 68% reached PASI 90 or higher. Moreover, nearly half of the cohort (44%) reached PASI 100. Further analysis showed that similar outcomes were reported through week 44. By this time point, 82% of patients reached PASI 50, 74% reached PASI 75, 65% reached PASI 90 and 46% reached PASI 100.”

To read more, click here.

(Source: October 19^th, 2022)